Xbiotech Stock Revenue
| XBIT Stock | USD 3.82 0.02 0.53% |
XBiotech fundamentals help investors to digest information that contributes to XBiotech's financial success or failures. It also enables traders to predict the movement of XBiotech Stock. The fundamental analysis module provides a way to measure XBiotech's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to XBiotech stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 345 K | 327.8 K |
XBiotech | Revenue |
XBiotech Company Revenue Analysis
XBiotech's Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current XBiotech Revenue | 300 K |
Most of XBiotech's fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, XBiotech is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of XBiotech
Projected quarterly revenue analysis of XBiotech provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of XBiotech match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in XBiotech's stock price.
XBiotech Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for XBiotech is extremely important. It helps to project a fair market value of XBiotech Stock properly, considering its historical fundamentals such as Revenue. Since XBiotech's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of XBiotech's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of XBiotech's interrelated accounts and indicators.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Based on the latest financial disclosure, XBiotech reported 300 K of revenue. This is 100.0% lower than that of the Biotechnology sector and 99.96% lower than that of the Health Care industry. The revenue for all United States stocks is 100.0% higher than that of the company.
XBiotech Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses XBiotech's direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of XBiotech could also be used in its relative valuation, which is a method of valuing XBiotech by comparing valuation metrics of similar companies.XBiotech is currently under evaluation in revenue category among its peers.
XBiotech Current Valuation Drivers
We derive many important indicators used in calculating different scores of XBiotech from analyzing XBiotech's financial statements. These drivers represent accounts that assess XBiotech's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of XBiotech's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 726.9M | 482.4M | 334.4M | 106.8M | 122.9M | 116.7M | |
| Enterprise Value | 12.3M | 245.0M | 97.4M | (50.5M) | (58.0M) | (55.1M) |
XBiotech ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, XBiotech's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to XBiotech's managers, analysts, and investors.Environmental | Governance | Social |
XBiotech Institutional Holders
Institutional Holdings refers to the ownership stake in XBiotech that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of XBiotech's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing XBiotech's value.| Shares | Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 75.7 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 72.5 K | Empowered Funds, Llc | 2024-09-30 | 62.6 K | Charles Schwab Investment Management Inc | 2024-09-30 | 58.4 K | Goldman Sachs Group Inc | 2024-09-30 | 40.4 K | Bnp Paribas Arbitrage, Sa | 2024-09-30 | 40 K | Fmr Inc | 2024-09-30 | 29 K | Barclays Plc | 2024-09-30 | 26.3 K | Nuveen Asset Management, Llc | 2024-09-30 | 24.9 K | Blackrock Inc | 2024-09-30 | 1.3 M | Vanguard Group Inc | 2024-09-30 | 1.1 M |
XBiotech Fundamentals
| Return On Equity | -0.16 | ||||
| Return On Asset | -0.12 | ||||
| Current Valuation | (56.67 M) | ||||
| Shares Outstanding | 30.48 M | ||||
| Shares Owned By Insiders | 35.10 % | ||||
| Shares Owned By Institutions | 16.19 % | ||||
| Number Of Shares Shorted | 770.65 K | ||||
| Price To Earning | 1.21 X | ||||
| Price To Book | 0.61 X | ||||
| Price To Sales | 12.23 X | ||||
| Revenue | 300 K | ||||
| Gross Profit | 3.36 M | ||||
| EBITDA | (35.77 M) | ||||
| Net Income | (24.56 M) | ||||
| Cash And Equivalents | 225.79 M | ||||
| Cash Per Share | 7.42 X | ||||
| Total Debt | 7.77 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 28.99 X | ||||
| Book Value Per Share | 6.31 X | ||||
| Cash Flow From Operations | (18.73 M) | ||||
| Short Ratio | 7.63 X | ||||
| Earnings Per Share | (1.08) X | ||||
| Target Price | 18.0 | ||||
| Number Of Employees | 82 | ||||
| Beta | 1.41 | ||||
| Market Capitalization | 116.45 M | ||||
| Total Asset | 226.62 M | ||||
| Retained Earnings | (52.31 M) | ||||
| Working Capital | 195.62 M | ||||
| Current Asset | 93.04 M | ||||
| Current Liabilities | 6.29 M | ||||
| Net Asset | 226.62 M |
About XBiotech Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze XBiotech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of XBiotech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of XBiotech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for XBiotech Stock Analysis
When running XBiotech's price analysis, check to measure XBiotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy XBiotech is operating at the current time. Most of XBiotech's value examination focuses on studying past and present price action to predict the probability of XBiotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move XBiotech's price. Additionally, you may evaluate how the addition of XBiotech to your portfolios can decrease your overall portfolio volatility.